Do fumonisins disrupt sphingolipid metabolism and cause intestinal barrier injury and liver stress with higher ALT?

Fumonisins are mycotoxins primarily produced by Fusarium species that contaminate maize-based products. These toxins are structurally similar to sphingoid bases, allowing them to interfere profoundly with cellular lipid signaling and structural integrity, leading to systemic physiological stress.

Mechanistic disruption of sphingolipid metabolism

The core toxicity of fumonisins, particularly Fumonisin B1 (FB1), stems from the potent inhibition of the enzyme ceramide synthase (CerS). By acting as a structural mimic of sphinganine (Sa) and sphingosine (So), fumonisins block the acylation of these bases into ceramides.

• Biomarker elevation: This inhibition causes a rapid accumulation of free sphinganine, which is often detected clinically as an increased Sa/So ratio.
• Cellular consequences: The resulting depletion of complex ceramides compromises membrane stability, while the buildup of bioactive sphingoid bases triggers mitochondrial dysfunction and apoptosis.

Intestinal barrier injury

Research indicates that the intestinal tract is a primary target for fumonisin-induced damage.

• Tight junction degradation: Exposure leads to the downregulation of critical tight junction proteins, including Claudin-1 and Claudin-4.
• Permeability: Studies using porcine models and human epithelial cell lines demonstrate a significant decrease in trans-epithelial electrical resistance (TEER), indicating increased paracellular permeability (often termed "leaky gut"). This disruption facilitates the translocation of pathogens and increases susceptibility to inflammatory secondary infections.

Liver stress and ALT elevation

The liver serves as a major site for fumonisin metabolism and toxicity.

• Hepatocyte damage: The disruption of sphingolipid pathways induces oxidative stress and endoplasmic reticulum (ER) stress within hepatocytes.
• Enzymatic markers: While direct human clinical trials are limited, animal models consistently show that the resulting hepatocellular necrosis and apoptosis lead to the release of alanine aminotransferase (ALT) into the bloodstream. FB1 is classified as a Group 2B carcinogen, reflecting its capacity for chronic hepatotoxic and pro-inflammatory effects.

Bottom line

Fumonisins directly disrupt sphingolipid metabolism by inhibiting ceramide synthase, which leads to compromised intestinal barrier integrity and liver stress. The mechanistic link between fumonisin-induced hepatocyte damage and elevated ALT is well-supported by animal and in vitro models, emphasizing the risk of systemic inflammation and organ stress following chronic exposure.